WEREWOLF THERAPEUTICS INC. - COMMON STOCK

4,8550

20-мая-24 15:08:04

15 мин. задержка

Акции

+0,1350

+2,86%

Сегодняшний диапазон

4,5700 - 4,9300

ISIN

N/A

Источник

NASDAQ

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

03 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 10:05:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

23 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

05 апр 2024 16:30:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

04 апр 2024 16:30:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

06 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

05 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

08 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

22 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

14 ноя 2023 16:25:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

31 окт 2023 09:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 сен 2023 09:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

11 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences

05 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

10 авг 2023 07:10:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

01 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

11 май 2023 07:00:00 Источник Nasdaq GlobeNewswire
Werewolf Therapeutics to Participate in May Investor Conferences

01 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.